FY2025 EPS Estimates for Pfizer Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Pfizer to $3.15, up from $3.09, maintaining a "Neutral" rating with a price objective of $24.00.
• In its latest quarterly earnings report, Pfizer exceeded expectations with $0.78 EPS on revenue of $14.65 billion, beating estimates and showing a 10.3% year-over-year revenue growth.
• The company has declared a quarterly dividend of $0.43, yielding 6.9%, to be paid out in September, with a current dividend payout ratio of 91.49%.

Pfizer Inc. (NYSE:PFE - Free Report) - Cantor Fitzgerald lifted their FY2025 earnings estimates for Pfizer in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $3.15 per share for the year, up from their previous estimate of $3.09. Cantor Fitzgerald currently has a "Neutral" rating and a $24.00 target price on the stock. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer's FY2026 earnings at $3.10 EPS.

Several other analysts have also recently weighed in on the stock. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Wolfe Research raised their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Up 0.2%

NYSE:PFE traded up $0.05 during mid-day trading on Friday, hitting $25.16. The stock had a trading volume of 31,819,451 shares, compared to its average volume of 45,227,284. The stock has a 50-day simple moving average of $24.60 and a two-hundred day simple moving average of $24.44. The company has a market capitalization of $143.05 billion, a PE ratio of 13.38, a PEG ratio of 0.89 and a beta of 0.52. Pfizer has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is presently 91.49%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of PFE. Vanguard Group Inc. increased its stake in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company's stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the period. Geode Capital Management LLC increased its stake in Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company's stock valued at $3,080,552,000 after buying an additional 1,820,634 shares during the period. Norges Bank acquired a new position in Pfizer in the 2nd quarter valued at $2,270,157,000. Northern Trust Corp increased its stake in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after buying an additional 3,943,397 shares during the period. Finally, Amundi increased its stake in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.